Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Energy
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form

[Disclosure] Hyundai Motor (005380) – Provisional Financial Results (Consolidated) / 2026-07-23

Posted on July 23, 2026August 11, 2026 By K-STOCK Editor No Comments on [Disclosure] Hyundai Motor (005380) – Provisional Financial Results (Consolidated) / 2026-07-23

Fact Source: Financial Supervisory Service DART

💡 3-Second Summary

For Q2 2026, Hyundai Motor Company reported provisional consolidated revenue of approximately KRW 49.22T and operating profit of approximately KRW 2.85T. Revenue and operating profit grew 7.1% and 13.4% QoQ respectively, though operating profit decreased 20.8% YoY. Cumulative H1 2026 revenue reached approximately KRW 95.15T (+2.7% YoY) and operating profit stood at KRW 5.37T (-25.8% YoY).

📊 [Key Disclosure Details & Financial Metrics]

  • Disclosure Type: Provisional Operating Results on a Consolidated Basis (Fair Disclosure)
  • Period: Q2 2026 (April 1, 2026 – June 30, 2026) & H1 2026 Cumulative
  • Key Financial Metrics (Unit: KRW Million):
    • Revenue: Q2 2026 KRW 49,215,328 (QoQ +7.1%, YoY +1.9%) / H1 Cumulative KRW 95,154,214 (YoY Cumulative +2.7%)
    • Operating Profit: Q2 2026 KRW 2,850,888 (QoQ +13.4%, YoY -20.8%) / H1 Cumulative KRW 5,365,574 (YoY Cumulative -25.8%)
    • Continuing Operations Profit Before Tax: Q2 2026 KRW 3,645,740 (QoQ +3.5%, YoY -16.9%) / H1 Cumulative KRW 7,167,251 (YoY Cumulative -19.0%)
    • Net Profit: Q2 2026 KRW 2,887,962 (QoQ +11.7%, YoY -11.2%) / H1 Cumulative KRW 5,472,888 (YoY Cumulative -17.5%)
    • Controlling Interest Net Profit: Q2 2026 KRW 2,520,851 (QoQ +7.9%, YoY -15.9%) / H1 Cumulative KRW 4,856,197 (YoY Cumulative -21.1%)
  • Other Key Matters: Figures are prepared in accordance with K-IFRS and represent unaudited internal settlement data prior to completion of external audit; actual finalized numbers may differ. Detailed materials are available on the company’s IR website.

📝 Editor’s Comment (Key Follow-up Checkpoint)

📌 Discrepancy Between Provisional and Finalized Figures and Periodic Report Disclosures

This disclosure presents provisional operating results for Q2 2026 based on unaudited internal accounting prior to external audit completion. Comparing these provisional figures with the finalized figures upon formal review is important for assessing the accuracy of the provisional data and understanding the company’s financial position. The finalized figures and detailed financial statements can be verified through subsequent periodic financial filings (such as the H1 half-year report) submitted to DART.

📢 Disclaimer & Source Notice

Source: This content was newly structured and generated based on official submission data from the Financial Supervisory Service’s DART system.

Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest entirely with the investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Automotive

Post navigation

Previous Post: [Disclosure] Hyundai Motor (005380) – Decision on Closure of Shareholders’ Register (Record Date) for Dividend / 2026-07-23
Next Post: [Disclosure] Samsung Electro-Mechanics (009150) – Material Sales/Supply Contract / 2026-07-23

Related Posts

[Disclosure] Hanwha Ocean (042660) – Sales and Supply Contract / 2025-04-28 Disclosures
[Disclosure] Hyundai Motor (005380) – Outlook on Sales Performance, Etc. (Fair Disclosure) / 2025-01-03 Disclosures
[Disclosure] Samsung Biologics (207940) – Sustainability Report and Related Matters (Voluntary Disclosure) / 2025-09-05 Disclosures
[Disclosure] Celltrion (068270) – Application for Amendment of Phase 3 Clinical Trial Plan for CT-P51 (Keytruda Biosimilar) in Korea / 2026-03-30 Disclosures
[Disclosure] Hanwha Systems (272210) – Investor Relations (IR) Holding / 2026-04-20 Disclosures
[Disclosure] SK hynix (000660 / SKHY) – Decision on Rights Offering / 2026-01-28 Semiconductors

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] KEPCO (015760 / KEP) – Provisional Consolidated Earnings Results / 2026-08-12August 12, 2026
  • [Disclosure] Hanwha Systems (272210) – Decision on Acquisition of Shares and Investment Certificates of Other Corporations (Correction) / 2026-08-10August 10, 2026
  • [Disclosure] KEPCO (015760 / KEP) – Financial Results Disclosure Schedule Announcement / 2026-08-07August 7, 2026
  • [Disclosure] KEPCO (015760 / KEP) – Investor Relations (IR) Holding Announcement / 2026-08-07August 7, 2026
  • [Disclosure] Hanwha Aerospace (012450) – Decision on Convening General Meeting of Shareholders / 2026-08-07August 7, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme